Morning Briefing
Summaries of health policy coverage from major news organizations
State Lawmakers Look For Ways To Blunt Rising Drug Prices
Should drug makers be required to disclose their costs to justify rising prices? This is what a growing number of state legislatures are considering. Over the past several weeks, lawmakers in a handful of states stretching from California to Massachusetts have introduced bills in a bid to force the pharmaceutical industry to conduct an economic striptease. (Silverman, 4/23)
Quest Diagnostics Inc. said Thursday that revenue grew 5.3% in its first quarter as the laboratory-testing company benefits from growth in its diagnostics business and an improving environment. Core profit narrowly topped Wall Street expectations, while revenue was in line. (Dulaney, 4/23)
Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first quarter of 2015, as cheaper copies of one of its bestsellers ate into sales. Sales were hit by the U.S. patent expiring on heartburn drug Nexium. The patent on cholesterol drug Crestor, another big seller, expires next year. (4/24)
